Soligenix rises after FDA clears ulcer drug for mid-stage study
30/11/2023 14:03
** Shares of Soligenix SNGX.O rise 39.7% to $0.58 in
premarket trade
** Drug developer says U.S. FDA has cleared its drug
dusquetide for a mid-stage study evaluating its efficacy against
oral and genital ulcers caused by Behçet's disease, a type of
blood vessel inflammation disease
** SNGX expects to begin patient enrollment in H2 2024
** Behçet's disease (BD) causes sores, ulcers, lesions,
rashes and eye inflammation
** As many as 1 mln people worldwide have BD, with 18,000 in
the U.S. - co
** Dusquetide had missed its primary goal in a late study
evaluating it as a treatment for Oral Mucositis, a disease in
which oral sores and ulcers are caused by chemotherapy
** Up to Wednesday's close, stock down 93.9% this year
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))